Professional Documents
Culture Documents
QC
Test Observed Result Method Unit Specimen
results
Real-time, reverse Nasopharageal
COVID-19 RT-PCR Negative N/A Pass
transcription PCR swab
Specific remarks:
Asymptomatic
Interpretation:
RESULT REMARK
Positive RNA specific to SARS-Cov-2 detected
Negative RNA specific to SARS-Cov-2 NOT detected
Inconclusive Result may be due to low viral load or bad sample quality. Re-testing of repeat sample is
recommended for confirmation.
GENERAL COMMENTS:
1. Testing for SARS-Cov-2 was performed using commercial US FDA, EUA, CE-IVD approved kits.
2. Negative results do not preclude SARS-Cov-2 and should not be used as the sole basis for patient management decisions.
Negative results must be combined with clinical observations, patient history and test should be repeated in case of high
suspicion.
3. Viral nucleic acid may persist in vivo independent of virus viability. Detection of the analyte target does not indicate that
the viruses are infectious or are causative agents of the observed symptoms.
4. False negative results may be attributed to improper sample collection, improper transport, treatment, PCR inhibitors etc.
5. NovaLAB Medical Ltd. does not take any responsibility for information provided by the patient/customer.
6. As per Mauritian law, all contact details and test results shall be communicated to the Ministry of Health and Wellness for
the timely initiation of contact tracing and appropriate control measures.
7. Limit of Detection for the RT-PCR kit = 5 copies/20uL reaction. Kits with low limits of detection (LOD) are more sensitive
to detecting low levels of viral RNA.
8. Results that are LOW POSITIVE (Ct values > 35) could represent either early phase of infection with rising levels or late
phase of infection with decreasing levels. Such results should be followed up by a repeat test a few days later.
9. Ct values stated above may be influenced by pre-analytical factors including sample type, sample collection, test kit used,
instrument used etc. and are not an indication of the severity of disease nor disease progression. It is recommended that
these values not be used in therapeutic or patient management-related decisions.
Authorized
Signatories:
Page 1 of 1